Cargando…

Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies

Pancreatic ductal adenocarcinoma (PDAC) exhibits a variety of phenotypes with regard to disease progression and treatment response. This variability complicates clinical decision-making despite the improvement of survival due to the recent introduction of FOLFIRINOX (FFX) and nab-paclitaxel. Questio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, Kimiyo N., Nakamura, Akira, Liu, Lin L., Stein, Shayna, Tramontano, Angela C., Kartoun, Uri, Shimizu, Tetsunosuke, Inoue, Yoshihiro, Asakuma, Mitsuhiro, Haeno, Hiroshi, Kong, Chung Yin, Uchiyama, Kazuhisa, Gonen, Mithat, Hur, Chin, Michor, Franziska
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485645/ https://www.ncbi.nlm.nih.gov/pubmed/31026288 http://dx.doi.org/10.1371/journal.pone.0215409

Ejemplares similares

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients
por: Stein, Shayna, et al.
Publicado: (2018)

Single port access for laparoscopic lateral segmentectomy
por: Inoue, Yoshihiro, et al.
Publicado: (2017)

A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability
por: Iwami, Shingo, et al.
Publicado: (2012)

Duodenal obstruction due to chronic pancreatitis of the pancreas tail treated by surgical intervention: A case report
por: Tomioka, Atsushi, et al.
Publicado: (2019)

A complete response to capecitabine and oxaliplatin chemotherapy in primary duodenal carcinoma with liver and nodal metastases: a case report
por: Hagihara, Seita, et al.
Publicado: (2018)

Long-term disease-free survival of an undifferentiated pleomorphic sarcoma of the spleen: A case report and literature review
por: Tomioka, Atsushi, et al.
Publicado: (2022)

Surgical management of intraoperatively diagnosed portal annular pancreas: Two case reports
por: Abe, Nobutaka, et al.
Publicado: (2021)

Surgical treatment of gastric venous congestion in association with extended resection of pancreas: a case report
por: Kagota, Shuji, et al.
Publicado: (2020)

Torsion of an accessory spleen: a rare case preoperatively diagnosed and cured by single-port surgery
por: Ozeki, Maiko, et al.
Publicado: (2015)

Combined resection of the gastroduodenal artery without revascularization in distal pancreatectomy with en bloc celiac axis resection (extended DP-CAR) for pancreatic cancer: A case report
por: Tomioka, Atsushi, et al.
Publicado: (2022)

Prediction of postoperative liver regeneration from clinical information using a data-led mathematical model
por: Yamamoto, Kimiyo N., et al.
Publicado: (2016)

Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
por: Cheng, Yu-Chen, et al.
Publicado: (2023)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Histone Modifications Are Associated with Transcript Isoform Diversity in Normal and Cancer Cells
por: Podlaha, Ondrej, et al.
Publicado: (2014)

Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
por: Chung, Moon Jae, et al.
Publicado: (2018)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

The usefulness of laparoscopic surgery for inguinal endometriosis
por: Mushiake, Shu, et al.
Publicado: (2023)

Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis
por: Hayashi, Michihiro, et al.
Publicado: (2010)

Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
por: KAYAHAN, Neslihan, et al.
Publicado: (2021)

Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies
por: Altrock, Philipp M., et al.
Publicado: (2018)

Stochastic Tunneling of Two Mutations in a Population of Cancer Cells
por: Haeno, Hiroshi, et al.
Publicado: (2013)

Single-port surgery (SPS) strategy for small bowel obstruction (SBO) caused by postoperative internal hernia: A series case report
por: Taniguchi, Kohei, et al.
Publicado: (2018)

Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
por: Ingram, Myles A., et al.
Publicado: (2022)

Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity
por: Zhang, Yue, et al.
Publicado: (2015)

Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer
por: de Jesus, Victor H. F., et al.
Publicado: (2020)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
por: Mita, Naoki, et al.
Publicado: (2019)

Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
por: Kim, Jung Hoon, et al.
Publicado: (2018)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020)

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
por: Schlick, Konstantin, et al.
Publicado: (2020)

Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
por: Williet, Nicolas, et al.
Publicado: (2021)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
por: Liu, Lin L., et al.
Publicado: (2015)

The Probable Cell of Origin of NF1- and PDGF-Driven Glioblastomas
por: Hambardzumyan, Dolores, et al.
Publicado: (2011)

The evolution of tumor metastasis during clonal expansion with alterations in metastasis driver genes
por: Yamamoto, Kimiyo N., et al.
Publicado: (2015)

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
por: Portal, Alix, et al.
Publicado: (2015)

Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
por: Hahn, Sarah, et al.
Publicado: (2017)

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
por: Vogl, Ursula M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_upd7v3sen4aibpvdh64etu1bs2